Cancer Research UK has entered into a clinical development collaboration with UCB SA of Belgium to advance two candidate antibody therapeutics for cancer into the clinic. Financial details of the partnership were not disclosed.
The deal is one of several involving the UK charity and its division Cancer Research Horizons with institutions and companies across Europe. In November 2022, Cancer Research UK reached an agreement with the Karolinska Institutet in Sweden to validate novel drug targets in cancer.